Company intelligence / Profile preview

Aurion Therapeutics

Seattle, Washington, United States

Ownership: Private
Employees: ~69
Development stage: Other

Overview

Vyznova (HCEC-1) launched commercially in Japan in 2024; AURN001 (US/EU candidate) demonstrated favorable safety and robust vision improvement in completed Phase 1/2 trial (97 subjects), with Phase 3 to begin in 2025/2026; technology enables 100+ doses from a single donor, minimally invasive with rapid patient recovery.

Therapeutic areas: Ophthalmology
Modalities: Cell therapyAllogeneic cell therapy
Industry: Biotech

Partnerships

Charles River Laboratories (CDMO for manufacturing clinical and commercial supply)

Beyond the preview

Go deeper on Aurion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurion Therapeutics.

Explore the full profile